Zina Affas

Zina Affas joined Atlas Venture in 2002 from Euromedica where she was an Executive Search Consultant specializing in Pharmaceutical and Biotechnology assignments in Europe.
Previously, she was a Scientific Analyst at the international law firm Shook, Hardy & Bacon where she worked in medical litigation and, in particular, pharmaceutical and tobacco product liability in Europe, Asia and the Middle East.
She works closely with portfolio companies Achillion (NASDAQ: ACHN), Cellzome, Neurotech, NovaMed, and Sirion.
She sits on the Board of Cellzome, NovaMed and Sirion.
Zina Affas holds a Pharmacy degree with Honors from the University of Nottingham and is a member of the Royal Pharmaceutical Society of Great Britain.
She obtained a Medicinal Chemistry Ph.D.
from the University of Nottingham where her research focused on establishing strategies toward the synthesis of bacterial signaling molecules and led to filing of the patent "Compounds and their use as antibacterial agents." The research is published in the Journal of Molecular Microbiology.